It has many products approved by CFDA of China, FDA of USA, EMA of EU and PMDA of Japan. The products cover many provinces and cities in China and are exported to more than 20 countries and regions such as USA, EU, Japan, South Korea and India
EBIC provides comprehensive customized services for domestic and foreign drug R & D enterprises, including the development and production of pharmaceutical intermediates and API. We accept all stages of the project, including the initial stage of scheme formation, laboratory scale synthesis, sample validation, process development, pilot test, and industrial production.
Provide API R & D application service throughout the whole drug development process. It can provide one-stop outsourcing services from process route development and verification, analysis method development and verification, process improvement and registration.
At present, we have successfully developed a series of new synthetic processes for liver diseases, anti-tumor drugs, cardio cerebrovascular drugs, hypoglycemic drugs, etc., which can provide a large number of initial raw materials, registered starting materials, GMP advanced intermediates and API for global pharmaceutical companies
It has many products approved by CFDA of China, FDA of USA, EMA of EU and PMDA of Japan. The products cover many provinces and cities in China and are exported to more than 20 countries and regions such as USA, EU, Japan, South Korea and India
EBIC provides comprehensive customized services for domestic and foreign drug R & D enterprises, including the development and production of pharmaceutical intermediates and API. We accept all stages of the project, including the initial stage of scheme formation, laboratory scale synthesis, sample validation, process development, pilot test, and industrial production.
Provide API R & D application service throughout the whole drug development process. It can provide one-stop outsourcing services from process route development and verification, analysis method development and verification, process improvement and registration.
At present, we have successfully developed a series of new synthetic processes for liver diseases, anti-tumor drugs, cardio cerebrovascular drugs, hypoglycemic drugs, etc., which can provide a large number of initial raw materials, registered starting materials, GMP advanced intermediates and API for global pharmaceutical companies